2025-12-20 - Analysis Report
Okay, let's break down the analysis of Recursion Pharmaceuticals (RXRX).

**0) Overview and Instructions Followed**

This report will present the data for Recursion Pharmaceuticals (RXRX) as requested, comparing it to the S&P 500 (VOO). The format will be: 1) Simple numbers, 2) Simple analysis of those numbers, 3) Consideration of recent news and analyst opinions, and 4) a comprehensive summary.

**1) Return Rate Comparison**

*   **Ticker:** RXRX
*   **Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery.
*   **RXRX Cumulative Return:** -31.02%
*   **VOO Cumulative Return:** 42.87%
*   **Divergence:**
    *   Maximum: 84.1
    *   Minimum: -74.4
    *   Current: -73.8
    *   Relative Divergence: 0.4

**Analysis:**

RXRX has significantly underperformed the S&P 500 over the period examined. The negative cumulative return of RXRX contrasts sharply with the positive return of VOO. The divergence data indicates that RXRX's underperformance is near its historical worst relative to VOO, as the relative divergence is very low.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha  | Beta | Cap(B) |
|------------|-------|-------|--------|------|--------|
| 2021-2023  | 22.0% | 81.0% | 26.0%  | -0.2 | 5.1    |
| 2022-2024  | 11.0% | 81.0% | -10.0% | 0.1  | 3.5    |
| 2023-2025  | 11.0% | 80.0% | -54.0% | 0.1  | 2.2    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate has decreased substantially from 22% to 11% over the periods.
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant risk and volatility.
*   **Alpha:** Alpha, which represents outperformance relative to the market, has declined dramatically and is now deeply negative, suggesting significant underperformance.
*   **Beta:** Beta is low (close to zero), implying that the stock has not been strongly correlated to market movements.
*   **Cap(B):** The market capitalization has been reduced from 5.1 to 2.2 Billion.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 4.26
*   **Previous Close:** 4.44
*   **Change:** -4.05%
*   **5-day SMA:** 4.356
*   **20-day SMA:** 4.4978
*   **60-day SMA:** 5.0218

**Analysis:**

The stock price is currently below all its moving averages (5-day, 20-day, and 60-day), indicating a downtrend. The recent price decrease of -4.05% suggests negative short-term momentum.

**3) RSI, PPO, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 46.19
*   **PPO:** 0.0634
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (225 shares - Very Safe - MRI:0.90) Monthly invest 1.7% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -4.7 (Indicates short-term decline)
*   **Expected Return (%):** -540.8%

**Analysis:**

*   The MRI suggests a medium investment risk level.
*   The RSI of 46.19 is neutral.
*   The PPO is also relatively neutral.
*   The negative change in relative divergence confirms recent underperformance.
*   The extremely negative expected return indicates substantial risk and potential for continued underperformance if held long-term.

**4) Recent News & Significant Events (Yahoo Finance)**

*   **Positive Catalyst:** Several headlines point to a recent upgrade by J.P. Morgan due to MEK inhibitor potential and positive trial data (REC-4881). This likely explains any recent upward price movement.
*   **Counterbalancing Negative News:** One article ("RXRX Stock: Analyzing the Dive and Its Impact") suggests there may be underlying concerns despite the upgrade, indicating the stock is volatile.
*   **Exscientia Merger & Clinical Data Readout:** Mentions of Exscientia merger and clinical data readout suggests the company is exploring strategic options.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean 2.50, ~Hold)
*   **Opinions:** 7
*   **Target Price (avg/high/low):** 7.00 / 11.00 / 3.00
*   **Recent Rating Changes:** Not specified in the prompt

**Analysis:**

While the analyst consensus leans towards "Buy," the mean rating is closer to "Hold." The average target price of $7.00 implies substantial upside potential from the current price. However, the wide range in target prices (3.00 to 11.00) suggests considerable uncertainty and differing opinions among analysts.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-11-05 | -0.36 | 0.01 B$    |
| 2025-08-05 | -0.41 | 0.02 B$    |
| 2025-05-05 | -0.5  | 0.01 B$    |
| 2024-11-06 | -0.34 | 0.03 B$    |
| 2025-11-05 | -0.34 | 0.03 B$    |

**Analysis:**

Recursion Pharmaceuticals has consistently reported negative EPS (Earnings Per Share), indicating unprofitability. Revenue is fluctuating but generally low. The negative EPS and low revenue are significant concerns.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-09-30 | $0.00B    | -194.74%      |
| 2025-06-30 | $0.02B    | -5.54%        |
| 2025-03-31 | $0.01B    | -47.31%      |
| 2024-12-31 | $0.00B    | -183.62%      |
| 2024-09-30 | $0.03B    | 53.69%      |

**Capital and Profitability:**

| Quarter    | Equity    | ROE    |
|------------|-----------|--------|
| 2025-09-30 | $1.05B    | -15.50% |
| 2025-06-30 | $0.92B    | -18.70% |
| 2025-03-31 | $0.93B    | -21.68% |
| 2024-12-31 | $1.03B    | -17.29% |
| 2024-09-30 | $0.52B    | -18.27% |

**Analysis:**

*   **Revenue:** Revenue is inconsistent and generally low, with some quarters at $0.00B.
*   **Profit Margin:** The profit margins are mostly negative, indicating the company is spending more than it earns.
*   **Equity:** Equity levels appear relatively stable, but are trending downward.
*   **ROE:** The negative Return on Equity reflects poor profitability and efficiency.

**7) Comprehensive Analysis**

Recursion Pharmaceuticals (RXRX) presents a mixed picture. While recent news indicates a J.P. Morgan upgrade and positive trial data, the stock has significantly underperformed the S&P 500. Technical indicators suggest a current downtrend. Key financial metrics reveal consistent losses, low revenue, and negative profit margins. Although analyst opinions are leaning towards "Buy," the consensus target price is optimistic, and a high level of uncertainty exists. The extremely negative expected return should give investors pause, and the high MDD should suggest higher risk when investing.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.